Eiger BioPharmaceuticals Inc. (EIGR) Rating Reiterated by Oppenheimer Holdings Inc.
Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)‘s stock had its “outperform” rating reiterated by equities researchers at Oppenheimer Holdings Inc. in a research note issued on Monday. They currently have a $34.00 price target on the stock. Oppenheimer Holdings Inc.’s price objective would indicate a potential upside of 166.67% from the stock’s current price.
Several other equities research analysts have also weighed in on EIGR. Zacks Investment Research lowered Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 10th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Eiger BioPharmaceuticals in a research report on Thursday, August 11th. Finally, Jefferies Group reissued a “buy” rating and set a $33.00 target price on shares of Eiger BioPharmaceuticals in a research report on Thursday, October 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Eiger BioPharmaceuticals has an average rating of “Buy” and a consensus target price of $34.00.
Eiger BioPharmaceuticals (NASDAQ:EIGR) traded down 3.01% during midday trading on Monday, reaching $12.90. 20,770 shares of the company’s stock were exchanged. The firm’s market capitalization is $107.79 million. The firm’s 50 day moving average is $12.49 and its 200 day moving average is $16.90. Eiger BioPharmaceuticals has a 52 week low of $10.71 and a 52 week high of $28.35.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Investment Management LLC raised its position in Eiger BioPharmaceuticals by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 12,459 shares of the company’s stock valued at $167,000 after buying an additional 104 shares during the period. Bank of New York Mellon Corp raised its position in Eiger BioPharmaceuticals by 14.3% in the third quarter. Bank of New York Mellon Corp now owns 12,319 shares of the company’s stock valued at $165,000 after buying an additional 1,541 shares during the period. Lombard Odier Asset Management USA Corp raised its position in Eiger BioPharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 143,638 shares of the company’s stock valued at $2,847,000 after buying an additional 3,950 shares during the period. Bridgeway Capital Management Inc. purchased a new position in Eiger BioPharmaceuticals during the second quarter valued at approximately $315,000. Finally, State Street Corp purchased a new position in Eiger BioPharmaceuticals during the second quarter valued at approximately $428,000. 39.95% of the stock is currently owned by institutional investors.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.